JPWO2022006309A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022006309A5 JPWO2022006309A5 JP2022581341A JP2022581341A JPWO2022006309A5 JP WO2022006309 A5 JPWO2022006309 A5 JP WO2022006309A5 JP 2022581341 A JP2022581341 A JP 2022581341A JP 2022581341 A JP2022581341 A JP 2022581341A JP WO2022006309 A5 JPWO2022006309 A5 JP WO2022006309A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- polypeptide
- recombinant
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 50
- 229920001184 polypeptide Polymers 0.000 claims description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 46
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 35
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 34
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 32
- 210000002865 immune cell Anatomy 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 19
- 101150076800 B2M gene Proteins 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 13
- 239000002299 complementary DNA Substances 0.000 claims description 11
- 230000000735 allogeneic effect Effects 0.000 claims description 10
- 210000000822 natural killer cell Anatomy 0.000 claims description 10
- 108020005004 Guide RNA Proteins 0.000 claims description 9
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 8
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 8
- 101710163270 Nuclease Proteins 0.000 claims description 8
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims description 7
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 claims description 5
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 2
- 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 claims 1
- 101710102159 Atrial natriuretic peptide receptor 2 Proteins 0.000 claims 1
- 210000004667 early pro-b cell Anatomy 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 210000003297 immature b lymphocyte Anatomy 0.000 claims 1
- 210000000014 large pre-b cell Anatomy 0.000 claims 1
- 210000002202 late pro-b cell Anatomy 0.000 claims 1
- 210000002809 long lived plasma cell Anatomy 0.000 claims 1
- 210000003826 marginal zone b cell Anatomy 0.000 claims 1
- 210000003519 mature b lymphocyte Anatomy 0.000 claims 1
- 210000001806 memory b lymphocyte Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000003720 plasmablast Anatomy 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 210000000345 small pre-b cell Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 241000894007 species Species 0.000 description 8
- 102000004547 Glucosylceramidase Human genes 0.000 description 4
- 108010017544 Glucosylceramidase Proteins 0.000 description 4
- 102000005840 alpha-Galactosidase Human genes 0.000 description 4
- 108010030291 alpha-Galactosidase Proteins 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 101150054399 ace2 gene Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000047279 human B2M Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047978P | 2020-07-03 | 2020-07-03 | |
| US63/047,978 | 2020-07-03 | ||
| US202063114131P | 2020-11-16 | 2020-11-16 | |
| US63/114,131 | 2020-11-16 | ||
| PCT/US2021/039953 WO2022006309A1 (en) | 2020-07-03 | 2021-06-30 | Methods and compositions for editing the b2m locus in b cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023532917A JP2023532917A (ja) | 2023-08-01 |
| JPWO2022006309A5 true JPWO2022006309A5 (https=) | 2024-07-04 |
| JP2023532917A5 JP2023532917A5 (https=) | 2024-07-04 |
Family
ID=79315579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581341A Pending JP2023532917A (ja) | 2020-07-03 | 2021-06-30 | Ｂ細胞のｂ２ｍ遺伝子座を編集するための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4175651A4 (https=) |
| JP (1) | JP2023532917A (https=) |
| KR (1) | KR20230035048A (https=) |
| CN (1) | CN116033910A (https=) |
| AU (1) | AU2021300358A1 (https=) |
| BR (1) | BR112022026534A2 (https=) |
| CA (1) | CA3186620A1 (https=) |
| IL (1) | IL299491A (https=) |
| MX (1) | MX2022015788A (https=) |
| WO (1) | WO2022006309A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250222138A1 (en) * | 2022-03-28 | 2025-07-10 | Ramot At Tel-Aviv University Ltd. | Site-specific in vivo t cell engineering, systems, compositions and methods thereof |
| CA3261942A1 (en) * | 2022-08-01 | 2024-02-08 | Idexx Laboratories, Inc. | FRACTIONAL ABUNDANCE DOSES OF HUMAN MOUSE |
| EP4698226A2 (en) * | 2023-04-17 | 2026-02-25 | Be Biopharma, Inc. | Engineered cell preparations for treatment of hemophilia |
| CN120866304A (zh) * | 2024-04-23 | 2025-10-31 | 南京奇迹生物科技有限公司 | 对b2m基因座的基因编辑方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073955A2 (en) * | 2014-11-06 | 2016-05-12 | President And Fellows Of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| IL297018A (en) * | 2015-12-18 | 2022-12-01 | Sangamo Therapeutics Inc | Directed cleavage of cell mhc receptor |
| US12144825B2 (en) * | 2017-06-30 | 2024-11-19 | Cellectis | Cellular immunotherapy for repetitive administration |
| US20200407713A1 (en) * | 2017-11-16 | 2020-12-31 | Mogam Institute For Biomedical Research | Transformed human cell and use thereof |
| US12378572B2 (en) * | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| CA3122131A1 (en) * | 2018-09-21 | 2020-03-26 | Zonghai Li | Method for gene editing of cell on the basis of crispr/cas system |
| UY38427A (es) * | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
-
2021
- 2021-06-30 MX MX2022015788A patent/MX2022015788A/es unknown
- 2021-06-30 WO PCT/US2021/039953 patent/WO2022006309A1/en not_active Ceased
- 2021-06-30 AU AU2021300358A patent/AU2021300358A1/en active Pending
- 2021-06-30 EP EP21832140.4A patent/EP4175651A4/en active Pending
- 2021-06-30 IL IL299491A patent/IL299491A/en unknown
- 2021-06-30 CA CA3186620A patent/CA3186620A1/en active Pending
- 2021-06-30 JP JP2022581341A patent/JP2023532917A/ja active Pending
- 2021-06-30 BR BR112022026534A patent/BR112022026534A2/pt unknown
- 2021-06-30 CN CN202180047549.4A patent/CN116033910A/zh active Pending
- 2021-06-30 KR KR1020237001885A patent/KR20230035048A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210009653A1 (en) | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule | |
| JP6538622B2 (ja) | ホモ二量体タンパク質コンストラクト | |
| JP6676759B2 (ja) | 抗原特異的ｔｃｒの新規生成 | |
| JP2021520202A5 (https=) | ||
| US20040241686A1 (en) | Her2/neu target antigen and use of same to stimulate an immune response | |
| JP2020509780A5 (https=) | ||
| US20260103504A1 (en) | Chimeric Antigen Receptor Polypeptides and Methods of Using Same | |
| JP2018524273A (ja) | クローディン−１８．２−特異的免疫受容体およびｔ細胞エピトープ | |
| JP2008545397A (ja) | 生物におけるイムノモデュレーションのための組成物および方法 | |
| US20140193449A1 (en) | Compositions and methods for cancer treatment | |
| Kroczek et al. | Structure-function relationship of XCL1 used for in vivo targeting of antigen into XCR1+ dendritic cells | |
| WO2022046730A2 (en) | Bcma chimeric antigen receptors | |
| IL299491A (en) | Methods and compositions for editing the b2m locus in b cells | |
| JPWO2020243719A5 (https=) | ||
| KR20060003903A (ko) | 사람 암배아 항원을 암호화하는 합성 유전자 및 이의 용도 | |
| JPWO2022006309A5 (https=) | ||
| JP7675833B2 (ja) | 内因性タンパク質分子で単一ドメイン抗体を置き換えたキメラ抗原受容体 | |
| JPWO2022216514A5 (https=) | ||
| US20230272431A1 (en) | Methods and compositions for editing the b2m locus in b cells | |
| EP4501954A1 (en) | A nucleic acid encoding a cd8 alpha beta co-receptor, cells and pharmaceutical compositions comprising the same | |
| Gan et al. | Gene therapy for hemophilia A | |
| CN1148381C (zh) | 新的人趋化因子巨噬细胞炎性蛋白、其编码序列及用途 | |
| WO1997007670A1 (fr) | Vertebre presentant une tolerance immunologique et procede d'utilisation de ce vertebre | |
| CN1237172C (zh) | 亚非马蜂镇静肽前体基因及其编码的多肽和制备方法 | |
| CN121079403A (zh) | 转座酶及其用途 |